S- (+)-Rolipram

Research use only, not for human use.

S-(+)-Rolipram inhibits human monocyte cyclic AMP-specific PDE4 with IC50 of 0.75 μM, has anti-inflammatory and anti-depressant activity in the central nervous system, less potent than its R enantiomer.

S-(+)-Rolipram inhibits human monocyte cyclic AMP-specific PDE4 with IC50 of 0.75 μM, has anti-inflammatory and anti-depressant activity in the central nervous system, less potent than its R enantiomer.(In Vitro):(+)-Rolipram (0.015-1000 μM; 20 h) dose-dependently suppress LPS-induced TNF production of human mononuclear cells (MNC), with an IC50 of 550 nM.(In Vivo):(+)-Rolipram (0.025-6.25 mg/kg; a single i.p.) dose-dependently inhibits locomotor activity and induces head twitches in rats.(+)-Rolipram (0.06-25 mg/kg; a single i.p.) causes a dose-related fall in rectal temperature of rats.

(+)-Rolipram (0.015-1000 μM; 20 h) dose-dependently suppress LPS-induced TNF production of human mononuclear cells (MNC), with an IC50 of 550 nM.

(+)-Rolipram (0.025-6.25 mg/kg; a single i.p.) dose-dependently inhibits locomotor activity and induces head twitches in rats.(+)-Rolipram (0.06-25 mg/kg; a single i.p.) causes a dose-related fall in rectal temperature of rats.

(+)-Rolipram | (S)-Rolipram

Others

Other Targets

PDE4

Inflammation/Immunology

——

85416-73-5

275.34

C16H21NO3

>98% (HPLC)

DMSO : 100 mg/mL. 363.19 mM;

COC1=C(OC2CCCC2)C=C(C=C1)[C@H]1CNC(=O)C1

——

(-20℃)

With Ice Pack

≥ 2 years